Aims: The 10-site Prescription Opioid Addiction Treatment Study, conducted in the NIDA Clinical Trials Network, examined different lengths of buprenorphine-naloxone (bup-nx) plus medical management, with or without additional counseling, for patients dependent upon prescription opioids. Among patients (N=360) receiving 12 weeks of bup-nx stabilization, 49% achieved successful opioid use outcomes at week 12. The aim […]

Aims: The purpose of this study was to evaluate the demographic, infectious disease status and clinical severity of dependence among heroin users compared to non-prescribed opioid analgesic users in a group of opioid dependent young adults seeking treatment with buprenorphine/naloxone. (Source: Drug and Alcohol Dependence)

Aims: The favorable clinical characteristics and improved treatment outcomes for prescription opioid dependent (POD) patients, and modest severity of withdrawal symptoms with buprenorphine/naloxone (bup/nx), have led physicians to offer detoxification with bup/nx for POD patients. We sought to determine whether bup/nx stabilization followed by detoxification (DTX) or maintenance (MTN) leads to greater reduction in illicit […]

Aims: To assess whether response to Cognitive Behavioral Therapy (CBT) differed between primarily prescription opioid users (POU) and primarily heroin users (HU) receiving primary care buprenorphine/naloxone (BUP) treatment with physician management (PM). (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.